Compare · CMMB vs NVS
CMMB vs NVS
Side-by-side comparison of Chemomab Therapeutics Ltd. (CMMB) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CMMB and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.62B, about 22357.7x CMMB ($12.7M).
- Over the past year, CMMB is down 65.2% and NVS is up 24.6% - NVS leads by 89.8 points.
- CMMB has hit the wire 3 times in the past 4 weeks while NVS has been quiet.
- NVS has more recent analyst coverage (25 ratings vs 5 for CMMB).
- Company
- Chemomab Therapeutics Ltd.
- Novartis AG
- Price
- $1.77-3.28%
- $147.10-1.32%
- Market cap
- $12.7M
- $284.62B
- 1M return
- -1.39%
- +1.13%
- 1Y return
- -65.16%
- +24.63%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 3
- 0
- Recent ratings
- 5
- 25
Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. engages in the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 16, 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest CMMB
- SEC Form 3 filed by new insider Melincoff Gwen A
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chief Executive Officer Mor George Adi disposed of 50,462 units of American Depositary Shares, decreasing direct ownership by 87% to 18,750 units (SEC Form 4)
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 6-K filed by Chemomab Therapeutics Ltd.
- SEC Form 3 filed by new insider Mor George Adi
- SEC Form 3 filed by new insider Darvish Nissim
- SEC Form 3 filed by new insider Cohen Neil Harris
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG